Integration of Bronchoscopic Transesophageal Ultrasound Examination of the Left Adrenal Gland into Routine Lung Cancer Staging Workup: A Prospective Trial.

BACKGROUND: Endobronchial ultrasound (EBUS) with transbronchial needle aspiration increases the diagnostic yield of lung cancer staging. The left adrenal gland (LAG) is a common site for lung cancer metastasis. The modality of transesophageal examination with an EBUS bronchoscope (EUS-B) routinely for LAG has not been assessed. OBJECTIVE: The aim of this study was to prospectively assess if evaluation and tissue sampling of the LAG could routinely be implemented in an EBUS procedure. METHODS: Patients referred for EBUS between March and August 2017 had assessment of the LAG via EUS-B. Fine-needle aspiration (FNA) was performed in cases with a suspicious LAG. The detection rate, procedure time, and learning curve of four experienced EBUS-bronchoscopists was assessed, plus the diagnostic accuracy and complication rate of FNA. RESULTS: In total, 313 consecutive patients were included. The overall LAG detection rate was 87.5%. After the initial learning curve, the detection rate for all four bronchoscopists was >93%. The detection rate did not correlate with any patient characteristics. EUS-B-FNA revealed nine LAG metastases, with a sensitivity, specificity, and accuracy of 75%, 100%, and 99%, respectively. The mean EUS-B operation time was 194.4 s, with 594.8 s for FNA. There were no FNA-associated complications. CONCLUSIONS: Evaluation of the LAG with EUS-B could routinely be included in an EBUS procedure if necessary. A high detection rate can be achieved after an initial learning period. FNA of the LAG was feasible and safe. EUS-B of the LAG could be integrated into the usual EBUS/EUS-B procedure in lung cancer staging workup.

Feasibility of intra-arterial chemotherapy for retinoblastoma: experiences in a large single center cohort study.

PURPOSE: In the last 10 years, intra-arterial chemotherapy (IAC) has been increasingly used in the clinical management of retinoblastoma. It is reported to provide tumor control even in advanced stage disease that might have previously required enucleation. In our clinical experience, there are three conditions that may impair the use of IAC: (1) significant collaterals to meningeal arteries, (2) technical failure of ophthalmic artery catheterization, or (3) retina blood supply from collaterals different to the ophthalmic artery. In the current study, we assessed the rate of IACs that could not be carried out in our institution due to these three reasons. METHODS: All patients admitted for IAC in our hospital were retrospectively assessed by chart review. Non-application rate of IAC was assessed and classified according to the three abovementioned criteria. Complication rate of both finalized and interrupted interventions was recorded. RESULTS: Ninety-eight patients (median age 21.4 months, range 5.3 months-10.5 years) were identified. IAC was performed in 69 (70.4%) patients and interrupted in 12 (12.2%) cases because of meningeal collaterals, in 8 (8.2%) because of technical failure to cannulate the ophthalmic artery, and in 9 (9.2%) because of alternative blood supply of the retina. CONCLUSION: The rather defensive approach that is pursued in our center resulted in an overall non-application rate of IAC around 30%. The relatively high probability of conditions that impair the use of IAC needs to be addressed adequately in the patient conversation prior to the procedure. Our rate of 8% of abstention from IAC due to technical limitations might be reduced by the application of more rigorous therapeutic approaches such as balloon occlusion of the distal internal carotid artery. More research is finally needed to determine if IAC can be safely performed in the presence of meningeal collaterals and via branches of the external carotid artery.

Third generation dual-energy CT with 80/150 Sn kV for head and neck tumor imaging.

BACKGROUND: Dual-energy CT (DECT) provides additional image datasets which enable improved tumor delineation or reduction of beam hardening artifacts in patients with head and neck squamous cell carcinoma (SCC). PURPOSE: To assess radiation dose and image quality of third-generation DECT of the head and neck in comparison to single-energy CT (SECT). MATERIAL AND METHODS: Thirty patients with SCC who underwent both SECT (reference tube voltage 120 kVp) and DECT (80/150 Sn kVp) of the head and neck region for staging were retrospectively selected. Attenuation measurements of the sternomastoid muscle, internal jugular vein, submandibular gland and tongue were compared. Image noise was assessed at five anatomic levels. Subjective image quality was evaluated by two radiologists in consensus. RESULTS: CTDIvol was 55% lower with DECT (4.2 vs. 9.3 mGy; P = 0.002). Median image noise was equal or lower in DECT at all levels (nasopharynx: 3.9 vs. 5.8, P < 0.0001; floor of mouth: 3.6 vs. 4.5, P = 0.0002; arytenoids: 3.6 vs. 3.1, P = 0.096; lower thyroid: 4.4 vs. 5.7, P = 0.002; arch of aorta: 5.6 vs. 6.5, P = 0.001). Attenuation was significantly lower in DECT ( P < 0.05). Subjective image analysis revealed that DECT is equal or superior to SECT with regard to overall image quality (nasopharynx: 5 vs. 5, P = 1; floor of mouth: 5 vs. 5, P = 0.0041; arytenoids: 5 vs. 5, P = 0.6; lower thyroid: 5 vs. 3, P < 0.0001; arch of aorta: 5 vs. 4, P < 0.0001). CONCLUSION: Head and neck imaging with third-generation DECT can reduce radiation dose by half compared to SECT, while maintaining excellent image quality.